Artia Global Partners LP Takes Position in Edgewise Therapeutics, Inc. $EWTX

Artia Global Partners LP acquired a new position in Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 98,800 shares of the company's stock, valued at approximately $4,014,000. Edgewise Therapeutics makes up 0.7% of Artia Global Partners LP's holdings, making the stock its 29th largest holding. Artia Global Partners LP owned approximately 0.09% of Edgewise Therapeutics at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Janus Henderson Group PLC lifted its stake in shares of Edgewise Therapeutics by 29.5% in the first quarter. Janus Henderson Group PLC now owns 5,915,556 shares of the company's stock worth $186,289,000 after buying an additional 1,348,706 shares during the last quarter. Persistent Asset Partners Ltd acquired a new position in Edgewise Therapeutics in the 2nd quarter valued at $2,821,000. UBS Group AG grew its stake in Edgewise Therapeutics by 1,755.0% in the 4th quarter. UBS Group AG now owns 2,117,073 shares of the company's stock valued at $52,535,000 after buying an additional 2,002,945 shares during the last quarter. California State Teachers Retirement System raised its holdings in Edgewise Therapeutics by 45.7% in the 1st quarter. California State Teachers Retirement System now owns 73,419 shares of the company's stock worth $2,313,000 after acquiring an additional 23,027 shares during the period. Finally, GSA Capital Partners LLP bought a new position in Edgewise Therapeutics in the 2nd quarter worth $1,807,000.

Analyst Ratings Changes

Several equities analysts recently weighed in on EWTX shares. Wedbush boosted their price objective on Edgewise Therapeutics from $46.00 to $52.00 and gave the stock an "outperform" rating in a research report on Monday, June 1st. JPMorgan Chase & Co. lifted their price target on Edgewise Therapeutics from $53.00 to $60.00 and gave the stock an "overweight" rating in a research report on Thursday, August 20th. Raymond James Financial reiterated a "strong-buy" rating and set a $66.00 price target on shares of Edgewise Therapeutics in a report on Monday, June 1st. The Goldman Sachs Group increased their price objective on Edgewise Therapeutics from $32.00 to $36.00 and gave the company a "neutral" rating in a research report on Tuesday, August 11th. Finally, Guggenheim raised their price objective on shares of Edgewise Therapeutics from $41.00 to $51.00 and gave the stock a "buy" rating in a research note on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $50.33.

Edgewise Therapeutics Trading Up 0.4%

Shares of NASDAQ EWTX opened at $44.38 on Thursday. The firm has a market capitalization of $4.82 billion, a price-to-earnings ratio of -23.99 and a beta of 0.30. Edgewise Therapeutics, Inc. has a one year low of $13.69 and a one year high of $48.40. The business has a fifty day simple moving average of $41.73 and a 200 day simple moving average of $35.55.

Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.47) by ($0.06). On average, research analysts anticipate that Edgewise Therapeutics, Inc. will post -2.09 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Edgewise Therapeutics news, General Counsel John R. Moore sold 5,016 shares of Edgewise Therapeutics stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $43.82, for a total transaction of $219,801.12. Following the completion of the transaction, the general counsel directly owned 17,697 shares of the company's stock, valued at approximately $775,482.54. This trade represents a 22.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Alan J. Russell sold 5,901 shares of the business's stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $43.73, for a total transaction of $258,050.73. Following the completion of the sale, the insider owned 31,466 shares in the company, valued at $1,376,008.18. This represents a 15.79% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 238,329 shares of company stock worth $9,557,529 in the last quarter. Corporate insiders own 21.30% of the company's stock.

Edgewise Therapeutics Company Profile

Edgewise Therapeutics, Inc NASDAQ: EWTX is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.

At the core of Edgewise's pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source